About Osiris Therapeutics (OTCMKTS:OSIR)
Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body's natural healing. The Company's products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company's BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Osiris Therapeutics (OTCMKTS:OSIR) Frequently Asked Questions
What is Osiris Therapeutics' stock symbol?
Osiris Therapeutics trades on the OTCMKTS under the ticker symbol "OSIR."
Who are some of Osiris Therapeutics' key competitors?
Some companies that are related to Osiris Therapeutics include Arrowhead Pharmaceuticals (ARWR), Odonate Therapeutics (ODT), Lannett (LCI), Rhythm Pharmaceuticals (RYTM), Fate Therapeutics (FATE), Progenics Pharmaceuticals (PGNX), BeyondSpring (BYSI), NuCana (NCNA), Reata Pharmaceuticals (RETA), ZIOPHARM Oncology (ZIOP), Rigel Pharmaceuticals (RIGL), Akebia Therapeutics (AKBA), Dicerna Pharmaceuticals (DRNA), Five Prime Therapeutics (FPRX), Mesoblast (MESO), Heska (HSKA), Oxford Biomedica (OXBDF) and Achaogen (AKAO).
Who are Osiris Therapeutics' key executives?
Osiris Therapeutics' management team includes the folowing people:
- Peter Friedli, Chairman of the Board (Age 62)
- Jason Keefer, Interim President, Chief Executive Officer (Age 45)
- Linda L. Chang, Chief Financial Officer (Age 51)
- Frank D. Czworka Jr., Vice President, General Manager of Wound Care (Age 46)
- Adrian P. Mollo, General Counsel (Age 41)
- Alla N. Danilkovitch Ph.D., Chief Scientific Officer (Age 51)
- Thomas M. Brandt Jr., Independent Director (Age 63)
- Thomas J. Knapp, Independent Director (Age 63)
- Willi Miesch, Independent Director
- Uwe Sommer, Independent Director
Has Osiris Therapeutics been receiving favorable news coverage?
Headlines about OSIR stock have been trending somewhat positive on Friday, Accern Sentiment reports. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Osiris Therapeutics earned a coverage optimism score of 0.10 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.94 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Osiris Therapeutics?
Shares of OSIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Osiris Therapeutics' stock price today?
One share of OSIR stock can currently be purchased for approximately $8.95.
How big of a company is Osiris Therapeutics?
Osiris Therapeutics has a market capitalization of $318.33 million.
How can I contact Osiris Therapeutics?
Osiris Therapeutics' mailing address is 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD, 21046. The biotechnology company can be reached via phone at 443-545-1800 or via email at [email protected]
MarketBeat Community Rating for Osiris Therapeutics (OSIR)MarketBeat's community ratings are surveys of what our community members think about Osiris Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Osiris Therapeutics (OTCMKTS:OSIR) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Osiris Therapeutics (OTCMKTS:OSIR) Earnings History and Estimates Chart
Osiris Therapeutics (OTCMKTS OSIR) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/6/2015||Q315||$0.06||($0.02)||$25.40 million||$24.30 million||View||N/A|
|8/5/2015||Q215||$0.06||$0.03||$23.60 million||$23.70 million||View||N/A|
|5/8/2015||Q115||$0.04||$18.40 million||$21.00 million||View||N/A|
|3/5/2015||Q414||$0.05||$0.03||$18.53 million||$19.50 million||View||N/A|
|11/7/2014||Q314||($0.01)||$0.02||$14.80 million||$17.20 million||View||N/A|
|8/7/2014||Q214||$0.16||($0.04)||$11.00 million||$13.30 million||View||N/A|
|5/12/2014||($0.08)||($0.02)||$9.00 million||$10.05 million||View||N/A|
|3/5/2014||Q413||$0.65||$0.11||$7.50 million||$8.10 million||View||N/A|
|11/1/2013||Q313||($0.10)||($0.05)||$6.70 million||$6.88 million||View||N/A|
|8/5/2013||Q2 2013||($0.09)||($0.11)||$4.35 million||$5.29 million||View||N/A|
|5/7/2013||Q1 2013||($0.09)||($0.08)||$3.53 million||$4.06 million||View||N/A|
|11/5/2012||Q312||($0.14)||($0.09)||$1.89 million||$2.15 million||View||N/A|
Osiris Therapeutics (OTCMKTS:OSIR) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Osiris Therapeutics (OTCMKTS:OSIR) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Osiris Therapeutics (OTCMKTS OSIR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 44.60%
Institutional Ownership Percentage: 0.27%
Osiris Therapeutics (OTCMKTS OSIR) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|5/27/2014||Matthew Paul Neumayer||Insider||Sell||3,750||$16.10||$60,375.00|| |
|5/21/2014||Philip Jacoby, Jr.||CFO||Sell||15,947||$15.43||$246,062.21||12,500|| |
|3/14/2014||Michelle Leroux Williams||Insider||Sell||61,934||$14.09||$872,650.06|| |
|11/25/2013||Philip Jacoby, Jr.||CFO||Sell||18,372||$15.99||$293,768.28||12,500|| |
|11/15/2013||Michelle Leroux Williams||Insider||Sell||24,500||$15.50||$379,750.00|| |
|8/20/2013||Matthew Paul Neumayer||Insider||Sell||11,375||$19.75||$224,656.25|| |
Osiris Therapeutics (OTCMKTS OSIR) News Headlines
Osiris Therapeutics (OTCMKTS:OSIR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Osiris Therapeutics (OTCMKTS:OSIR) Income Statement, Balance Sheet and Cash Flow Statement
Osiris Therapeutics (OTCMKTS OSIR) Stock Chart for Friday, March, 23, 2018